title: Survival of patients with pathologic T0N+ oral and oropharyngeal cancer after neoadjuvant therapy and surgery: the minority report.
abstract: OBJECTIVE
  Treatment outcome of patients with oral and oropharyngeal squamous cell carcinoma (OOSCC) achieving complete pathologic response at the primary site (ypT0) but incomplete response in loco-regional lymph nodes after preoperative chemoradiation (ypN+) is poorly described in the literature. This study's objective was to assess the survival of patients with OOSCC with ypT0N+ disease.
  
  
  METHODS
  176 patients with primary locally advanced OOSCC undergoing preoperative chemoradiotherapy were stratified according to the pathologic TNM classification into 6 groups: ypT0N0M0 (46%), ypT0N+M0 (10%), ypTNM I (24%), ypTNM II (4%), ypTNM III (6%), and ypTNM IV (10%).
  
  
  RESULTS
  Three-year overall survival (OS) and recurrence-free survival (RFS) rates for the ypT0N+M0 group were both 61.8% and were similar to those of the ypTNM I group (OS 62.4%; RFS rate of 59.2%).
  
  
  CONCLUSIONS
  Survival analyses showed that patients with OOSCC with ypT0N+ disease have a similar prognosis to those with pathologic TNM stage I.
authors.affiliation: Department of Cranio-, Maxillofacial, and Oral Surgery, Medical University of Vienna, Vienna, Austria. christos.perisanidis@meduniwien.ac.at
authors.forename: Christos
authors.initials: C
authors.lastname: Perisanidis
authors.forename: Irene
authors.initials: I
authors.lastname: Sulzbacher
authors.forename: Martina
authors.initials: M
authors.lastname: Mittlböck
authors.forename: David
authors.initials: D
authors.lastname: Mitchell
authors.forename: Cornelia
authors.initials: C
authors.lastname: Czembirek
authors.forename: Rudolf
authors.initials: R
authors.lastname: Seemann
authors.forename: Rolf
authors.initials: R
authors.lastname: Ewers
authors.forename: Christian
authors.initials: C
authors.lastname: Schopper
authors.forename: Edgar
authors.initials: E
authors.lastname: Selzer
mesh_terms: D000328:Adult; D000368:Aged; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002294:Carcinoma, Squamous Cell / Q000601:surgery / Q000628:therapy*; D059186:Chemoradiotherapy, Adjuvant; D015331:Cohort Studies; D018572:Disease-Free Survival; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D005500:Follow-Up Studies; D006801:Humans; D008198:Lymph Nodes / Q000473:pathology; D008297:Male; D008875:Middle Aged; D016685:Mitomycin / Q000008:administration & dosage; D009062:Mouth Neoplasms / Q000601:surgery / Q000628:therapy*; D020360:Neoadjuvant Therapy; D060787:Neoplasm Grading; D009364:Neoplasm Recurrence, Local / Q000473:pathology; D009367:Neoplasm Staging; D009959:Oropharyngeal Neoplasms / Q000601:surgery / Q000628:therapy*; D011379:Prognosis; D012074:Remission Induction; D012189:Retrospective Studies; D015996:Survival Rate; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000903:Antibiotics, Antineoplastic; D000964:Antimetabolites, Antineoplastic; D016685:Mitomycin; D005472:Fluorouracil